Valanx GmbH

VALANX is developing new approaches for bioconjugation. The products of this process, the bioconjugates, are needed to produce particularly specific drugs, special diagnostics or biosensors. VALANX supplies special compounds that react quickly and are cost-effective in order to produce targeted and specific conjugates. With its revolutionary technology, VALANX promises to make the conjugates usable as a tool for completely new industrial applications.

Investment date

March 2020

Industry sector

Biotechnology

Want to see more investments?

To the overview

Cookie-Settings

We use cookies to ensure that we give you the best experience on our website. You can choose which cookies you want to allow below. You can find more details in our privacy policy.

Essential

Essential cookies are cookies that are required for the website to function properly.

Google Maps

Purpose	Representation of the company's location using Google's map service.
Data	Date and time of visit, location information, IP address, URL, usage data, search terms, geographic location.
Gesetzt von	Google Ireland Limited
Privacy Policy	https://policies.google.com/privacy

Statistical cookies

Analysing user behaviour (page views, number of visitors and visits, downloads), creating pseudonymous user profiles based on cross-device information of logged-in Google users (cross-device tracking), enriching pseudonymous user data with target group-specific information provided by Google, retargeting, UX testing, conversion tracking and retargeting in connection with Google Ads.